04Dec 2024
Prasugrel Outperforms Ticagrelor in Real-World ACS Study

Prasugrel Outperforms Ticagrelor in Real-World ACS Study

The propensity score–matched cohort study analyzed data from 17,642 acute coronary syndrome (ACS) patients undergoing invasive treatment to evaluate the safety and effectiveness of ticagrelor vs prasugrel. Over a 1-year follow-up, prasugrel was associated with a lower incidence of the composite endpoint (all-cause mortality, MI, or stroke: HR 1.24; 95% CI 1.12-1.37), with significant reductions in myocardial infarction (HR 1.20) and stroke (HR 1.33). No significant differences in stent thrombosis or major bleeding were observed. Findings underscore prasugrel's potential as a preferred agent in ACS, especially in ST-segment elevation MI cases.

  • #cardiology

Like

Save

Share